A Peek At How Janssen’s Supply Chain Withstood COVID-19 Disruptions
Exec Outlines Preparedness To Distribute COVID-19 Vaccine
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
You may also be interested in...
Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead
CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.